Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys
- PMID: 14740950
- DOI: 10.4269/ajtmh.2003.69.12
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys
Erratum in
- Am J Trop Med Hyg. 2004 Mar;70(3):336
Abstract
Dengue (DENV) virus strains for each of the four DENV serotypes were modified by passage in primary dog kidney (PDK) cell cultures with final manufacture of vaccine lots in fetal rhesus monkey diploid cell cultures. "Strain sets" consisting of serially-passaged DENV were inoculated in rhesus monkeys along with unmodified parent viruses for each strain. Vaccine candidates were compared with unmodified parent viruses by measuring viremia and immune responses. All except one DENV-1 strain demonstrated reduced infection in monkeys after PDK cell passage. A DENV-3 strain lost all monkey infectivity after PDK cell passage. Twelve vaccine candidates were selected for Phase 1 human trials through this selection process.
Similar articles
-
Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.Am J Trop Med Hyg. 1984 Jul;33(4):679-83. doi: 10.4269/ajtmh.1984.33.679. Am J Trop Med Hyg. 1984. PMID: 6476215
-
Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):17-23. doi: 10.4269/ajtmh.2003.69.17. Am J Trop Med Hyg. 2003. PMID: 14740951 Clinical Trial.
-
Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii.Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):5-11. doi: 10.4269/ajtmh.2003.69.6_suppl.0690005. Am J Trop Med Hyg. 2003. PMID: 14740949
-
Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):1-4. doi: 10.4269/ajtmh.2003.69.6_suppl.0690001. Am J Trop Med Hyg. 2003. PMID: 14756126 Review. No abstract available.
-
A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Expert Rev Vaccines. 2016;15(4):497-508. doi: 10.1586/14760584.2016.1128328. Epub 2016 Feb 22. Expert Rev Vaccines. 2016. PMID: 26635182 Review.
Cited by
-
Vaccines and immunization strategies for dengue prevention.Emerg Microbes Infect. 2016 Jul 20;5(7):e77. doi: 10.1038/emi.2016.74. Emerg Microbes Infect. 2016. PMID: 27436365 Free PMC article. Review.
-
Transcriptional activation of interferon-stimulated genes but not of cytokine genes after primary infection of rhesus macaques with dengue virus type 1.Clin Vaccine Immunol. 2007 Jun;14(6):756-66. doi: 10.1128/CVI.00052-07. Epub 2007 Apr 11. Clin Vaccine Immunol. 2007. PMID: 17428947 Free PMC article.
-
Anti-dengue Vaccines: From Development to Clinical Trials.Front Immunol. 2020 Jun 18;11:1252. doi: 10.3389/fimmu.2020.01252. eCollection 2020. Front Immunol. 2020. PMID: 32655561 Free PMC article. Review.
-
Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.BMC Infect Dis. 2004 Oct 4;4:39. doi: 10.1186/1471-2334-4-39. BMC Infect Dis. 2004. PMID: 15461822 Free PMC article.
-
Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.Antimicrob Agents Chemother. 2005 Nov;49(11):4508-14. doi: 10.1128/AAC.49.11.4508-4514.2005. Antimicrob Agents Chemother. 2005. PMID: 16251289 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical